Reported 3 months ago
Wall Street is expressing ongoing anxiety regarding the impact of GLP-1 weight loss drugs on medical device manufacturers, particularly after Dexcom reduced its profit forecasts. Despite concerns, competitors like Abbott and Medtronic remain unaffected, and industry experts note that supply constraints rather than demand have primarily shaped the market dynamics. Furthermore, both continuous glucose monitoring devices and bariatric surgeries remain underutilized, presenting opportunities for growth amidst increased competition from emerging GLP-1 drugs.
Source: YAHOO